

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

tofacitinib 11 mg extended-release (Xeljanz XR 11 mg)

Notes:

- Quantity Limits: Yes
- * Intolerance excludes adverse drug reactions that are expected, mild in nature, resolve with continued treatment, and do not require medication discontinuation

Initiation (new start) criteria: Non-formulary **tofacitinib 11 mg extended-release (Xeljanz XR 11 mg)** will be covered on the prescription drug benefit when the following criteria are met:

1. Prescriber is a rheumatologist and patient has a diagnosis of rheumatoid arthritis/inflammatory arthritis
 - Patient has tried and failed/intolerant to as least 1 of the following:
 - Methotrexate
 - Hydroxychloroquine
 - Sulfasalazine
 - Leflunomide
 - Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
 - Patient is not currently taking any other medications dosed more than one time a day
2. Prescriber is a rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient has tried and failed/intolerant to or has contraindication to methotrexate (methotrexate not required if patient has dactylitis [inflammation of finger or toe])
 - Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
 - Patient has tried and failed/intolerant to or has a contraindication to secukinumab product (criteria based)
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing

kp.org

Revised: 07/14/22
Effective: 09/01/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

tofacitinib 11 mg extended-release (Xeljanz XR 11 mg)

- Patient is not currently taking any other medications dosed more than one time a day
3. Prescriber is a rheumatologist and patient has a diagnosis of ankylosing spondylitis/spondyloarthritis
 - Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
 - Patient is not currently taking any other medications dosed more than one time a day
 4. Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis
 - Patient has tried and failed/intolerant to at least 1 of the following:
 - Infliximab product (unless documented by prescriber that patient is unable to attend infusion appointments)
 - Adalimumab product (criteria based)
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
 - Patient is not currently taking any other medications dosed more than one time a day

Criteria for *new members* entering Kaiser Permanente already taking the medication who have not been reviewed previously:

1. Prescriber is a rheumatologist and patient has a diagnosis of rheumatoid arthritis/inflammatory arthritis
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
 - Patient is not currently taking any other medications dosed more than one time a day
2. Prescriber is a rheumatologist and patient has a diagnosis of psoriatic arthritis
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing

kp.org

Revised: 07/14/22
Effective: 09/01/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest

Criteria-Based Consultation Prescribing Program

CRITERIA FOR DRUG COVERAGE

tofacitinib 11 mg extended-release (Xeljanz XR 11 mg)

- Patient is not currently taking any other medications dosed more than one time a day
3. Prescriber is a dermatologist or rheumatologist and patient has a diagnosis of ankylosing spondylitis
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
 - Patient is not currently taking any other medications dosed more than one time a day
 4. Prescriber is a gastroenterologist and patient has a diagnosis of ulcerative colitis
 - Patient has had previous trial of tofacitinib immediate release (5 mg twice daily) with documented concerns about adherence to twice daily dosing
 - Patient is not currently taking any other medications dosed more than one time a day

kp.org

Revised: 07/14/22
Effective: 09/01/22

All plans offered and underwritten by
Kaiser Foundation Health Plan of the Northwest